Article
mTOR inhibition augments antitumor immune effector response by reprogramming the TP53-mutant, immune-cold HNSCC tumor microenvironment.
Neoplasia (New York, N.Y.) - 1 Oct 2026
Nath Priyatosh, Khandelwal Alok, Li Chun, Moore-Medlin Tara, Vasudevan Srivatsa Surya, Alvarez Victor Albornoz, Franco Omar E, Gutkind J Silvio, Nathan Cherie-Ann O
Abstract excerpt
Resistance to immunotherapy remains a major clinical challenge in TP53-mutant head and neck squamous cell carcinoma (HNSCC), a disease subset characterized by immune exclusion, high recurrence, and poor outcomes. Given the constitutive activation of PI3K/AKT/mTOR signaling in TP53-mutant HNSCC and its role in disease progression, we investigated whether the mTOR inhibition (mTORi) could overcome immune resistance...
Read the complete abstract on PubMedTopics
- Tumor Microenvironment
- Animals
- Tumor Suppressor Protein p53
- Humans
- MTOR Inhibitors
